新型口服抗凝药在经皮左心耳封堵术后应用的研究进展

doi:10.20047/j.issn1673-7210.2023.21.12

摘要
图/表
参考文献(34)
相关文章 (15)

全文: PDF (517 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要心房颤动包括瓣膜性心房颤动与非瓣膜性心房颤动，具有发病率高、预后差等特点，严重威胁人类生命健康。经皮左心耳封堵术（PLAAC）已经广泛应用于治疗存在高出血风险或有口服抗凝药物禁忌证的非瓣膜性心房颤动患者，虽然PLAAC用于治疗难以耐受抗凝治疗风险的患者有一定的风险，但其仍然是治疗心房颤动患者的重要举措。器械相关血栓、缺血性脑卒中为PLAAC术后常见的并发症，临床上常采用华法林、维生素K拮抗剂等抗凝药物治疗，但这些药物的实际使用效果往往是次优的。目前，各指南推荐PLAAC术后以抗凝治疗为主的方案，抗凝治疗尤其是新型口服抗凝药（NOACs）在PLAAC术后应用的安全性与有效性仍需要进一步研究。本文归纳并探讨NOACs在PLAAC术后的应用研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王玮　　王永

关键词 ：新型口服抗凝药, 经皮左心耳封堵术, 并发症, 安全性, 有效性

Abstract：Atrial fibrillation includes valvular atrial fibrillation and non-valvular atrial fibrillation. It has the characteristics of high morbidity and poor prognosis, which seriously threatens human life and health. Percutaneous left atrial appendage closure (PLAAC) has been widely used in the treatment of patients with non-valvular atrial fibrillation who have a high risk of bleeding or contraindications to oral anticoagulants. Although PLAAC has some risks for patients who have difficulty tolerating the risks of anticoagulant therapy, it remains an important step in the treatment of patients with atrial fibrillation. Device-related thrombus and ischemic stroke are common complications after PLAAC. Anticoagulant drugs such as Warfarin and vitamin K antagonists are often used in clinical treatment, but the actual effect of these drugs is often sub-optimal. At present, various guidelines recommend the regimentation of anticoagulation therapy after PLAAC surgery, the safety and effectiveness of anticoagulation therapy, especially the novel oral anticoagulant (NOACs) after PLAAC surgery still needs further research. This article summarizes and discusses the application research of NOACs after PLAAC surgery.

Key words： Novel oral anticoagulants Percutaneous left atrial appendage closure Complications Security Effectiveness

引用本文:

王玮　　王永. 新型口服抗凝药在经皮左心耳封堵术后应用的研究进展[J]. 中国医药导报, 2023, 20(21): 58-61.
WANG Wei WANG Yong. Research progress on the application of novel oral anticoagulants after percutaneous left atrial appendage closure. 中国医药导报, 2023, 20(21): 58-61.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.21.12 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I21/58

[1] 陈美容.预防非瓣膜性心房颤动行经皮左心耳封堵术并发症患者的护理[J].护士进修杂志，2018，33（14）：1305- 1307.
[2] Ntaios G，Papavasileiou V，Diener HC，et al. Nonvitamin-K- antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack：An updated systematic review and meta-analysis of randomized controlled trials [J]. Int J Stroke，2017，12（6）：589-596.
[3] Doherty JU，Gluckman TJ，Hucker WJ，et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation：A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force [J]. J Am Coll Cardiol，2017，69（7）：871-898.
[4] 仲程豪，杨兵，周秀娟.经皮左心耳封堵术后的抗凝/抗血小板药物治疗方案[J].医学综述，2018，24（14）：2823- 2827.
[5] Vuddanda V，Turagam MK，Umale NA，et al. Incidence and causes of in-hospital outcomes and 30-day readmissions after percutaneous left atrial appendage closure：A US nationwide retrospective cohort study using claims data [J]. Heart Rhythm，2020，17（3）：374-382.
[6] 中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，心房颤动防治专家工作委员会，等.左心耳干预预防心房颤动患者血栓栓塞事件：目前的认识和建议（2019）[J].中华心律失常学杂志，2019，23（5）：372-392.
[7] Kusumoto FM，Bailey KR，Chaouki AS，et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death：A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [J]. Circulation，2018，138（13）：392-414.
[8] Dukkipati SR，Kar S，Holmes DR，et al. Device-Related Thr- ombus After Left Atrial Appendage Closure：Incidence，Predictors，and Outcomes [J]. Circulation，2018，138（9）：874- 885.
[9] Fauchier L，Cinaud A，Brigadeau F，et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation [J]. J Am Coll Cardiol，2018， 71（14）：1528-1536.
[10] Reddy VY，Doshi SK，Kar S，et al. 5-Year Outcomes After Left Atrial Appendage Closure：From the PREVAIL and PROTECT AF Trials [J]. J Am Coll Cardiol，2017，70（24）：2964-2975.
[11] 赵瑞骅.高龄老年非瓣膜性心房颤动患者应用新型口服抗凝药（NOACs）抗凝治疗有效性及安全性评价研究[D].太原：山西医科大学，2017.
[12] 赵紫楠，朱愿超，梁良，等.急性冠状动脉综合征患者应用新型口服抗凝药后发生大出血及心血管事件风险的meta分析[J].药物不良反应杂志，2019，21（4）：244-251.
[13] 陈文明，张美祥，张广求.新型口服抗凝药治疗急性冠状动脉综合征预后的Meta分析[J].药物流行病学杂志，2018，27（10）：647-653.
[14] 徐长禄，孙莉莉，张磊，等.口服抗凝药治疗静脉血栓栓塞症的现状及研究进展[J].国际输血及血液学杂志，2018，41（5）：451-456.
[15] Kubo S，Mizutani Y，Meemook K，et al. Incidence，Characteristics，and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients [J]. JACC Clin Electrophysiol，2017，3（12）：1380-1386.
[16] Garot P，Cormier B，Horvilleur J. Device-Related Thrombus After Left Atrial Appendage Closure [J]. Interv Cardiol，2019，14（1）：42-44.
[17] Alkhouli M，Busu T，Shah K，et al. Incidence and Clinical Impact of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion：A Meta-Analysis [J]. JACC Clin Electrophysiol，2018，4（12）：1629-1637.
[18] Bergmann MW，Betts TR，Sievert H，et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure：three-month data from the EWOLUTION prospective，multicentre，monitored international WATCHMAN LAA closure registry [J]. EuroIntervention，2017，13（7）：877-884.
[19] Cochet H，Iriart X，Sridi S，et al. Left atrial appendage patency and device-related thrombus after percutaneous left atrial appendage occlusion：a computed tomography study [J]. Eur Heart J Cardiovasc Imaging，2018，19（12）：1351-1361.
[20] Fastner C，Behnes M，Sartorius B，et al. Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines [J]. Int J Mol Sci，2018，19（2）：500.
[21] Enomoto Y，Gadiyaram VK，Gianni C，et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device [J]. Heart Rhythm，2017，14（1）：19-24.
[22] 陈雨意，陈艳红，张勇华，等.新型口服抗凝药物用于经皮左心耳封堵术术中、术后抗凝的初步临床随访结果[J].中国介入心脏病学杂志，2018，26（10）：547-552.
[23] Osmancik P，Herman D，Neuzil P，et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation [J]. J Am Coll Cardiol，2020，75（25）：3122-3135.
[24] 罗文龙，裴汉军，张新会.经皮左心耳封堵术预防非瓣膜性心房颤动患者发生缺血性脑卒中的研究进展[J].中华实用诊断与治疗杂志，2020，34（5）：535-537.
[25] Bhagirath VC，Cosyns B，Eikelboom JW. NOACs only for those who cannot tolerate a VKA：where is the evidence? [J]. Acta Cardiol，2019，74（1）：17-20.
[26] Verdecchia P，Angeli F，Aita A，et al. Why switch from warfarin to NOACs? [J]. Intern Emerg Med，2016，11（3）：289-293.
[27] He B，Jiang LS，Hao ZY，et al. Combination of ablation and left atrial appendage closure as “One-stop” procedure in the treatment of atrial fibrillation：Current status and future perspective [J]. Pacing Clin Electrophysiol，2021，44（7）：1259-1266.
[28] Santucci A，Byrne RA，Baumbach A，et al. Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey [J]. EuroIntervention，2016，12（1）：112-118.
[29] Schulman S，Singer D，Ageno W，et al. NOACs for treatment of venous thromboembolism in clinical practice [J]. Thromb Haemost，2017，117（7）：1317-1325.
[30] 孙红娜，郑玉粉，于锋.新型口服抗凝药的药物相互作用[J].中国医院药学杂志，2021，41（3）：314-320.
[31] Lau YC，Lip GY. New advances in the treatment of atrial fibrillation：focus on stroke prevention [J]. Expert Opin Pharmacother，2014，15（15）：2193-2204.
[32] Qazi AH，Wimmer AP，Huber KC，et al. Resolution（and Late Recurrence）of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran [J]. Echocardiography，2016，33（5）：792-795.
[33] 张明，刘德敏，崔炜.新型口服抗凝药在经导管主动脉瓣膜植入术中应用的研究进展[J].中国心血管杂志，2020，25（1）：73-76.
[34] 刘岳，任怡荣，朱火兰，等.新型口服抗凝药物在非瓣膜性心房颤动患者中的应用及挑战[J].中国全科医学，2020，23（23）：2872-2873，2894.